Insmed CEO exercises options, sells 10,700 shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
INSMED Inc Chair and CEO William Lewis exercised stock options for 10,700 shares of common stock on July 23, 2026, at exercise prices of $30.46 and $17.16, then sold 10,700 shares at weighted average prices of $105.62 and $106.43 under a Rule 10b5-1 trading plan adopted on September 4, 2025. He continues to hold 233,924 shares indirectly through a trust.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,700 shares ($868K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Lewis William
Role
Chair and CEO
Sold
10,700 shs ($1.13M)
Approx. gross sale proceeds
$1.13M
Approx. exercise cost
$267K
Approx. pre-tax spread
$868K
Share of Position Sold
4.0%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F4 | 6,260 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F4 | 4,440 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 6,260 | $30.46 | $191K |
| Exercise | Common Stock F1 | 4,440 | $17.16 | $76K |
| Sale | Common Stock F1, F2 | 4,828 | $105.62 | $510K |
| Sale | Common Stock F1, F3 | 5,872 | $106.43 | $625K |
| Holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 0 options (Direct);
Common Stock — 259,058 shares (Direct);
Common Stock — 233,924 shares (Indirect, By trust)
Holdings Before and After:
Stock Option (right to buy), 10,700 to 0 options (Direct);
Common Stock, 259,058 to 259,058 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (4)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Key Figures
Options exercised: 6,260 shares at $30.4600
Options exercised: 4,440 shares at $17.1600
Shares sold (block 1): 4,828 shares at $105.6200
+4 more
7 metrics
Options exercised
6,260 shares at $30.4600
Stock options exercised into common stock; expiration 2028-01-04
Options exercised
4,440 shares at $17.1600
Stock options exercised into common stock; expiration 2027-05-17
Shares sold (block 1)
4,828 shares at $105.6200
Weighted average sale price; actual prices $105.09–$106.02 per share
Shares sold (block 2)
5,872 shares at $106.4300
Weighted average sale price; actual prices $106.09–$106.78 per share
Net shares sold
10,700 shares
Total common shares sold in open-market transactions on 2026-07-23
Indirect holdings after transactions
233,924 shares
Common stock held indirectly by trust as of 2026-07-23
10b5-1 plan adoption date
September 4, 2025
Date William Lewis adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average sales price, Stock Option (right to buy), vesting schedule, +1 more
5 terms
Rule 10b5-1 trading plan financial
"transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"This is the weighted average sales price representing 4,828 shares sold"
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) with underlying Common Stock"
vesting schedule financial
"The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
indirect ownership financial
"Common Stock total_shares_following_transaction 233,924.0000 with nature_of_ownership: By trust"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Insmed (INSM) CEO William Lewis report on July 23, 2026?
William Lewis exercised stock options for 10,700 shares of Insmed common stock and sold 10,700 shares the same day in open-market transactions, reflecting an option exercise followed by partial monetization of the resulting shares.
Were the Insmed (INSM) stock trades by William Lewis made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by William Lewis on September 4, 2025, indicating the trades followed a pre-established schedule rather than discretionary same-day decisions.
What option grants were exercised in the latest Insmed (INSM) insider filing?
Lewis exercised options covering 6,260 shares at $30.46 per share, expiring January 4, 2028, and 4,440 shares at $17.16 per share, expiring May 17, 2027. These option exercises generated the common shares that were subsequently sold in part.
AI-generated analysis. How Rhea-AI works. Not financial advice.
